Adverum Biotechnologies, Inc.
ADVMDelisted Dec 9, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501756
Adverum Biotechnologies, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 10, 2025; 50 institutions reported holding it in 13F filings for Q3 2025, worth $63.8M in total; no superinvestor held it.
13F holders, Q4 2025
Institutional positions in Adverum Biotechnologies, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ADVM is no longer listed, and 13F filings after Q3 2025 list far fewer holders. See Q3 2025
- Institutional holders
- 0
- −50 vs. Q3 2025
- Shares held
- 0
- −14.1M (−100.0%) vs. Q3 2025
- Total value
- $0
- −$63.8M (−100.0%) vs. Q3 2025
- New holders
- 0
- 0 more added
- Sold out
- 50
- 0 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADVM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 50 | $63.8M |
| Q2 2025 | 59 | $30.1M |
| Q1 2025 | 71 | $69.8M |
| Q4 2024 | 70 | $74.1M |
| Q3 2024 | 77 | $120.2M |
| Q2 2024 | 68 | $117.7M |
| Q1 2024 | 61 | $236.9M |
| Q4 2023 | 61 | $48.3M |
| Q3 2023 | 61 | $97.9M |
| Q2 2023 | 58 | $104.4M |
| Q1 2023 | 55 | $45.0M |
| Q4 2022 | 59 | $33.2M |
| Q3 2022 | 78 | $55.6M |
| Q2 2022 | 77 | $70.0M |
| Q1 2022 | 92 | $82.4M |
| Q4 2021 | 98 | $115.5M |
| Q3 2021 | 110 | $151.2M |
| Q2 2021 | 118 | $280.4M |
| Q1 2021 | 132 | $937.9M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Adverum Biotechnologies, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 0 | $0 | 0.00% | −3,057,526−100.0% | Sold out |
| Principia Wealth Advisory, LLC | 0 | $0 | 0.00% | −2,077,946−100.0% | Sold out |
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −2,077,431−100.0% | Sold out |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −1,668,174−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −872,041−100.0% | Sold out |
| 5AM Venture Management, LLC | 0 | $0 | 0.00% | −541,666−100.0% | Sold out |
| Versant Venture Management, LLC | 0 | $0 | 0.00% | −506,821−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −402,581−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −363,496−100.0% | Sold out |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −363,282−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −324,422−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −311,394−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −287,246−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −234,541−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −184,762−100.0% | Sold out |
| Regeneron Pharmaceuticals, Inc. | 0 | $0 | 0.00% | −180,909−100.0% | Sold out |
| Warren Averett Asset Management, LLC | 0 | $0 | 0.00% | −160,991−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −88,670−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −68,734−100.0% | Sold out |
| Quinn Opportunity Partners LLC | 0 | $0 | 0.00% | −41,418−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −38,071−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −28,367−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −28,058−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −26,255−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −21,730−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −17,555−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −17,267−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −17,153−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −13,465−100.0% | Sold out |
| JustInvest LLC | 0 | $0 | 0.00% | −12,805−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,655−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −11,271−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,585−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −3,614−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1,933−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1,689−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −540−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −217−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −182−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −102−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| GHP Investment Advisors, Inc. | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Sound Income Strategies, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |